9th Sep 2020 16:04
Synairgen PLC - respiratory drug discovery and development firm - Submits patent application for use of inhaled interferon beta protein to treat virus-induced exacerbations in sufferers of chronic obstructive pulmonary disease. Synairgen has previously filed patent for inhaled interferon beta to treat Covid-19 patients.
Current stock price: 185.70 pence
Year-to-date change: up sharply from 5.88p on December 31
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Synairgen